New combo shot aims to simplify type 2 diabetes management
NCT ID NCT06716424
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a fixed-dose combination of insulin glargine and lixisenatide (iGlarLixi) in 105 adults with type 2 diabetes whose blood sugar is not well controlled on oral drugs or other injectables. The main goal is to check safety and side effects, while also measuring changes in blood sugar levels over time. All participants receive the same treatment, so there is no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
insulin glargine/lixisenatide (iGlarLixi)
What this could lead to
If successful, this could offer a convenient single-injection option to help people with type 2 diabetes better control their blood sugar.
What could go wrong
This is a single-arm, phase 4 study with no comparison group, so results may be less definitive. Side effects like low blood sugar or gastrointestinal issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 3560001
Kolkata, 700020, India
-
Investigational Site Number : 3560003
Kanpur, 208002, India
-
Investigational Site Number : 3560005
Hyderabad, 500034, India
-
Investigational Site Number : 3560006
Indore, 452010, India
-
Investigational Site Number : 3560007
Delhi, 110088, India
-
Investigational Site Number : 3560008
Pune, 411004, India
-
Investigational Site Number : 3560009
Bengaluru, 560054, India
-
Investigational Site Number : 3560011
Jaipur, 302020, India
-
Investigational Site Number : 3560014
Visakhapatnam, 530040, India
-
Investigational Site Number: 3560013
Pune, 411057, India